Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) [Phase 4]

View source ↗

Summary

Phase 4 multicenter randomized trial comparing esomeprazole 20 mg and 40 mg daily to placebo for heartburn and sleep disturbances in gastroesophageal reflux dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Esomeprazole (Esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 4 | Status: COMPLETED